Focus: COUR Pharmaceuticals is a nanoparticle-focused pharmaceutical company headquartered in Skokie, IL developing therapies across neurology and other therapeutic areas. The company operates at an early-stage development phase with a diverse pipeline spanning multiple indications.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
COUR offers early-stage nanotech platform experience but represents high execution risk for career stability; suitable only for risk-tolerant candidates seeking foundational biotech exposure.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for COUR Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from COUR Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Allergen-Encapsulating Nanoparticles Reprogram Pathogenic Allergen-Specific Th2 Cells to Suppress Food Allergy.
Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial.
Showing 5 of 10 publications